当前位置:
X-MOL 学术
›
Curr. Opin. Nephrol. Hypertens.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Current Opinion in Nephrology and Hypertension ( IF 2.2 ) Pub Date : 2021-05-10 , DOI: 10.1097/mnh.0000000000000716 J David Smeijer 1 , Donald E Kohan 2 , David J Webb 3 , Neeraj Dhaun 3, 4 , Hiddo J L Heerspink 1
Current Opinion in Nephrology and Hypertension ( IF 2.2 ) Pub Date : 2021-05-10 , DOI: 10.1097/mnh.0000000000000716 J David Smeijer 1 , Donald E Kohan 2 , David J Webb 3 , Neeraj Dhaun 3, 4 , Hiddo J L Heerspink 1
Affiliation
To summarize new clinical findings of endothelin receptor antagonists (ERA) in various etiologies of kidney disease targeted in clinical trials.
中文翻译:
内皮素受体拮抗剂用于治疗糖尿病和非糖尿病慢性肾病。
总结内皮素受体拮抗剂 (ERA) 在临床试验中靶向的各种肾病病因中的新临床发现。
更新日期:2021-05-17
中文翻译:
内皮素受体拮抗剂用于治疗糖尿病和非糖尿病慢性肾病。
总结内皮素受体拮抗剂 (ERA) 在临床试验中靶向的各种肾病病因中的新临床发现。